Mobile website
Archive > Volume 20 Issue 4 > 2013,20(4):449-455. DOI:10.3872/j.issn.1007-385X.2013.04.012 Prev Next
Clinical Research
Clinical efficiency of dendritic cells and cytokine-induced killer cells on local advanced and advanced pancreatic cancer patients
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To investigate the safety and efficiency of dendritic cells (DCs) combined with cytokine-induced killer (CIK) cells in the treatment of local advanced and advanced pancreatic cancer. Methods: Peripheral blood mononuclear cells (PBMCs) were collected from 24 pancreatic cancer patients in Ⅲ-Ⅳ stage from the department of tumor bio-therapy of No.81 Hospital of PLA during Jul. 2011 to May. 2012 and were cultured in vitro to obtain DC and CIK cells. DCs were sensitized by PANC1 (pancreatic cancer cell line) cell lysates and then transfused to pancreatic cancer patients combined with CIK cells. The changes in peripheral blood lymphocyte subsets, serum tumor markers and clinical efficiency were evaluated before and after DC-CIK cell treatment. Results: The proportions of CD3+ T cells, CD8+T cells and CD4+CD25+Treg were significantly decreased after DC-CIK cell treatment for 3 months (all P<0.05), while the ratio of CD4+/CD8+ cells was significantly increased (1.1±0.7 vs 1.5±0.9, P<0.05). The serum tumor marker CA19-9 level declined 1 month after-treatment (382.8±277.7 vs 213.8±214.6, P<0.05) and 3 months after-treatment (2138±214.6 vs 1540±118.2, P<0.01). In all the 24 patients, there was no case of complete response, 3 cases of partial response, 4 cases of stable disease, 17 cases of progressive disease; the clinical response rate was 12.5% and the disease control rate was 29.2%; the median survival time was 5.7 months; the 6- and 9-month overall survival rates were 33% and 27%, respectively. No grade 3-4 adverse events were observed in all cases during treatment. Conclusion: DCs combined with CIK cell treatment on local advanced and advanced pancreatic cancer patients are safe and feasible. DC-CIK treatment could increase patient's immune function and show clinical benefits.
Keywords:
Project Supported:
Project supported by the Medical Science and Technology Innovation Foundation of Nanjing Military Command of PLA（No. 08MB055）
Clc Number:
